Tag:
Shire
Latest Headlines
Latest Headlines
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
New chief takes helm at Promedior and steers a course for Boston
Just a couple of months after Promedior lined up its $21.5 million D round for fibrosis drug work, a new CEO has stepped up to the helm with plans to abandon Philadelphia and head for the bustling biotech hub in Boston.
Shire picks up Pervasis in potential $200M deal
Shire didn't disclose the exact deal terms in its announcement today, but the deal could be worth up to $200 million.
Promethera Biosciences banks $31M to fund PhI/II stem cell trial
Belgium's Promethera Biosciences has raised a bit more than $31 million to fund a Phase I/II study of its lead stem cell therapy, with Boehringer Ingelheim and Shire ( $SHPGY ) leading a pack of...
Growing popularity of virtual biotechs promises boon to outsourcers
The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire has helped spotlight the growing virtual biotech model.
Shire snaps up CNS program from startup Heptares, commits $190M in 'biobucks'
Heptares Therapeutics has revealed another major tie-up with a big drugmaker. A unit of Ireland-based Shire ( $SHPGY ) has exercised an option to grab global rights to Heptares' preclinical...
Shire yanks BLA for Fabry treatment in surprise about-face
In a surprising turn of events, Shire ( $SHPGY ) announced late yesterday that it is jerking its application for Replagal, the rare genetic disorder drug that the FDA had pushed to get on the market as Genzyme sorted out its high-profile manufacturing problems. The reason for the sudden reversal? The FDA is indicating the need for new clinical studies before it stamps an OK on the treatment for Fabry disease. And that put any approval off to "the distant future," the company said.
As Shire gives up on Replagal in U.S., Sanofi stands to gain
Sanofi ( $SNY ) may want to thank its lucky stars that its new Genzyme plant won FDA approval when it did. The facility in Framingham, MA, will allow the French drugmaker's rare-disease unit to get back on track with its Fabry disease drug Fabrazyme . It may also have deterred Shire from pursuing its own Fabry drug application in the face of complications at the FDA.
FerroKin buyout underscores potential of the virtual biotech
One of the big discussions in biotech in recent years has centered on the virtual business model. With IPOs hard to pull off, it just made more sense to many in the venture community to back a new generation of small developers with one or two programs that could be pushed into mid-stage development and then sold off. A host of global outsourcers made it possible to efficiently stage clinical studies.
Shire pits Vyvanse against Concerta in ADHD trials
Shire is taking aim at Johnson & Johnson's ( $JNJ ) Concerta . The Irish drugmaker is sponsoring two head-to-head trials pitting its ADHD drug Vyvanse against the J&J product as a treatment for adolescents with the disorder.
